Skip to main content
    P

    Palvella Therapeutics, Inc (PVLA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $144.60
    -7.88 (-5.17%)

    Market Cap: $2.23B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Palvella Therapeutics, Inc (PVLA) Earnings: Report Dates and Results

    Updated Nov 5, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Palvella Therapeutics (PVLA) is expected to report earnings on Mar 29, 2027. In the quarter ended Sep 30, 2026, Palvella Therapeutics reported EPS of -$1.70, below the -$1.65 estimate. It beat the EPS estimate in 1 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    11%(1/9)
    Avg Surprise
    -176.12%

    Upcoming Estimates

    Reports Mar 29, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$2.15
    Range-$2.68 - -$1.72
    17 analysts
    Revenue Consensus
    N/A
    RangeN/A
    18 analysts
    Reports May 5, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$2.07
    Range-$2.40 - -$1.70
    5 analysts
    EPS Revisions
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago-$2.27+8.9%
    60d ago-$2.27+8.9%
    30d ago-$2.27+8.9%
    7d ago-$2.18+5.2%
    Current-$2.07
    Revenue Consensus
    N/A
    RangeN/A
    7 analysts

    Next Report

    PVLA has an expected report date of Mar 29, 2027.

    PVLA Earnings Call

    The latest PVLA earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 9 quarters below that had an estimate, PVLA beat 1 and missed 8. The widest gap in the table came in the quarter ended Dec 31, 2024, when EPS landed 798.74% below the estimate.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$1.70-$1.65-$2.31 - -$1.05-3.03%MissN/A130 up, 1 downNov 5, 2026N/A
    Jun 30, 2026-$1.52-$1.16-$1.42 - -$0.86-31.03%MissN/A122 up, 6 downAug 4, 2026N/A
    Mar 31, 2026-$1.20-$0.93-$1.15 - -$0.77-29.03%MissN/A113 up, 4 downMay 7, 2026N/A
    Dec 31, 2025-$1.08-$0.91-$1.06 - -$0.30-18.58%MissN/A132 up, 0 downMar 31, 2026N/A
    Sep 30, 2025-$1.03-$0.85-$0.99 - -$0.63-21.18%MissN/A112 up, 4 downNov 11, 2025N/A
    Jun 30, 2025-$0.86-$0.77N/A-11.69%MissN/AN/AN/AAug 14, 2025N/A
    Mar 31, 2025-$0.74-$3.40N/A+78.24%BeatN/A30 up, 0 downMay 15, 2025N/A
    Dec 31, 2024-$5.37-$0.60-$0.70 - -$0.39-798.74%MissN/A30 up, 0 downMar 31, 2025N/A
    Sep 30, 2024-$2.19N/AN/AN/AN/AN/AN/AN/ANov 13, 2024N/A
    Jun 30, 2024-$2.76-$0.03N/AN/AN/A-169.1%N/AN/AAug 14, 2024N/A
    Mar 31, 2024-$3.95-$0.06N/AN/AN/AN/AN/AN/AMay 15, 2024$53000
    Dec 31, 2023-$3.71-$0.12N/AN/AN/AN/AN/AN/AMar 29, 2024$1.30M
    Sep 30, 2023-$8.70-$0.11N/AN/AN/AN/AN/AN/ANov 14, 2023$19.52M
    Jun 30, 2023$4.00-$0.16N/AN/AN/AN/AN/AN/AAug 10, 2023$20.05M
    Mar 31, 2023-$14.40-$0.18N/AN/AN/AN/AN/AN/AMay 10, 2023$1.94M
    Dec 31, 2022-$8.80-$0.23N/AN/AN/AN/AN/AN/AMar 29, 2023$5.85M
    Sep 30, 2022-$10.40-$0.16N/AN/AN/AN/AN/AN/ANov 2, 2022$5.37M
    Jun 30, 2022-$11.20-$0.11N/AN/AN/AN/AN/AN/AAug 4, 2022$3.70M
    Mar 31, 2022-$5.60-$0.12N/AN/AN/AN/AN/AN/AMay 11, 2022$10.99M
    Dec 31, 2021-$12.00-$0.14N/AN/AN/AN/AN/AN/AMar 1, 2022$8.44M
    Sep 30, 2021-$19.20-$0.24N/AN/AN/AN/AN/AN/ANov 2, 2021$4.06M
    Jun 30, 2021-$20.00-$0.22N/AN/AN/AN/AN/AN/AAug 4, 2021$3.29M
    Mar 31, 2021-$5.60-$0.17N/AN/AN/AN/AN/AN/AMay 17, 2021$15.63M
    Dec 31, 2020-$20.80-$0.23N/AN/AN/AN/AN/AN/AMar 30, 2021$1.88M
    Sep 30, 2020-$20.80-$0.13N/AN/AN/AN/AN/AN/ANov 4, 2020$2.94M
    Jun 30, 2020-$7.20-$0.17N/AN/AN/AN/AN/AN/AAug 10, 2020$11.25M
    Mar 31, 2020-$5.60-$0.17N/AN/AN/AN/AN/AN/AMay 11, 2020$13.26M
    Dec 31, 2019-$4.80-$0.28N/AN/AN/AN/AN/AN/AMar 12, 2020$17.27M
    Sep 30, 2019-$4.00-$0.17N/AN/AN/AN/AN/AN/ANov 11, 2019$15.13M
    Jun 30, 2019-$19.20-$0.22N/AN/AN/AN/AN/AN/AAug 7, 2019$5.33M
    Mar 31, 2019-$16.00-$0.20N/AN/AN/AN/AN/AN/AMay 8, 2019$8.54M
    Dec 31, 2018-$17.60-$0.18N/AN/AN/A-222.2%N/AN/AMar 20, 2019$4.91M
    Sep 30, 2018-$8.80-$0.12N/AN/AN/AN/AN/AN/ANov 7, 2018$8.35M
    Jun 30, 2018-$0.30-$0.01N/AN/AN/AN/AN/AN/AAug 9, 2018$11.69M
    Mar 31, 2018-$0.17-$0.02N/A-750.00%MissN/AN/AN/AMay 10, 2018$4.15M
    Dec 31, 2017$14.40-$0.07N/AN/AN/AN/AN/AN/AMar 9, 2018$18.15M
    Sep 30, 2017-$12.72N/AN/AN/AN/AN/AN/AN/ANov 9, 2017$3.93M
    Jun 30, 2017-$18.59N/AN/AN/AN/AN/AN/AN/AAug 10, 2017$1.85M
    Mar 31, 2017-$14.85N/AN/AN/AN/AN/AN/AN/AMay 11, 2017$1.34M
    Dec 31, 2016-$12.19N/AN/AN/AN/AN/AN/AN/AMar 23, 2017N/A
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$3.71, after -$14.28 the year before. It was -$43.57 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$3.71N/A
    Dec 31, 2024-$14.28N/A
    Dec 31, 2023-$22.81N/A
    Dec 31, 2022-$36.00N/A
    Dec 31, 2021-$56.80N/A
    Dec 31, 2020-$54.40N/A
    Dec 31, 2019-$44.00N/A
    Dec 31, 2018-$26.87N/A
    Dec 31, 2017-$31.76N/A
    Dec 31, 2016-$43.57N/A

    Earnings Calls

    The 2 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,500 words across 11 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20268,51011
    2026Q2Jun 30, 20268,26013

    2026Q3 Earnings Call

    Opening remarks

    Bohan Wei Vice President of Corporate Development and New Product Planning Thank you, operator. Good morning, and thank you for joining Palvella Therapeutics' Third Quarter 2026 financial results and corporate update call. As a reminder, our press release detailing today's announcements can be found in the Investors section of our website at www.palvellatx.com. On today's call, you will first hear from Wesley H. Kaupinen, our founder and executive officer, followed by Ashley Kline, our chief commercial officer, Dr. Jeff Martini, our chief scientific officer, and Matthew E. Korenberg, our chief financial officer. Before we begin, please note that today's remarks may include forward-looking statements regarding our development programs, regulatory strategy, commercial planning, and financial outlook. These statements are based on current assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. Please refer to our SEC filings for a full discussion of these risk factors. And now, I will turn the call over to Wesley.

    Wesley H. Kaupinen Founder and Executive Officer Thanks, Bohan. Good morning, everyone, and thank you all for joining us on Palvella Therapeutics' Third Quarter earnings call and corporate update. For children and adults living with microcystic lymphatic malformations, every day counts. Microcystic lymphatic malformations are a serious, rare, and chronically debilitating genetic disease. Starting at a young age, daily life can be impacted by persistent leaking and bleeding from lymphatic lesions, functional impairment, infections, disfigurement, and the physical and psychological burden of living with a lifelong infiltrative disease that progressively worsens over time. Despite this profound burden of disease, there are currently no FDA-approved therapies for microcystic lymphatic malformations. Last Wednesday, October 28, a major milestone was achieved that could soon change the treatment paradigm for individuals living with microcystic lymphatic malformations. Our team at Palvella Therapeutics announced that the FDA has accepted our new drug application for QTORIN rapamycin for the treatment of microcystic LMs, and furthermore, that the program has been granted the FDA's priority review designation. This designation is for medicines that, if approved, would offer significant improvements in the safety or effectiveness of treating serious conditions, and it sets a six-month FDA review goal rather than the standard 10-month review. In light of this milestone, I want to take a moment to recognize the patients and families who have participated in our clinical studies, our clinical investigators, our patient advocacy collaborators, our highly dedicated employees, and everyone who helped us reach this important point. Thank you. Furthermore, 116 days from today, on February 28, 2027, the Palvella team, working in conjunction with our physician and patient advocacy collaborators, will have the potential opportunity to begin transforming the lives of these patients through the commercialization of QTORIN rapamycin, if approved. Our goal is not simply to bring another medicine to market.

    Frequently Asked Questions About PVLA

    When is Palvella Therapeutics's next earnings date?

    Palvella Therapeutics's next earnings report is expected for Mar 29, 2027.

    Did PVLA beat earnings estimates last quarter?

    No. Palvella Therapeutics reported EPS of -$1.70 for the quarter ended Sep 30, 2026, below the -$1.65 estimate by 3.03%.

    What EPS do analysts expect from PVLA next quarter?

    The consensus EPS estimate for Palvella Therapeutics for the quarter ending Dec 31, 2026 is -$2.15 from 17 analysts, with estimates from -$2.68 to -$1.72.

    How often does PVLA beat earnings estimates?

    Palvella Therapeutics beat the EPS estimate in 1 of the last 8 quarters, with an average surprise of -104.38%.